Jules L. Dienstag

35.6k total citations · 12 hit papers
268 papers, 27.2k citations indexed

About

Jules L. Dienstag is a scholar working on Epidemiology, Hepatology and Infectious Diseases. According to data from OpenAlex, Jules L. Dienstag has authored 268 papers receiving a total of 27.2k indexed citations (citations by other indexed papers that have themselves been cited), including 194 papers in Epidemiology, 190 papers in Hepatology and 42 papers in Infectious Diseases. Recurrent topics in Jules L. Dienstag's work include Hepatitis B Virus Studies (150 papers), Hepatitis C virus research (125 papers) and Liver Disease Diagnosis and Treatment (102 papers). Jules L. Dienstag is often cited by papers focused on Hepatitis B Virus Studies (150 papers), Hepatitis C virus research (125 papers) and Liver Disease Diagnosis and Treatment (102 papers). Jules L. Dienstag collaborates with scholars based in United States, Canada and United Kingdom. Jules L. Dienstag's co-authors include Eugene R. Schiff, Jay H. Hoofnagle, Girish N. Vyas, Karen L. Lindsay, William M. Lee, John G. McHutchison, Herbert L. Bonkovsky, Anna S. Lok, Robert P. Perrillo and Timothy R. Morgan and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Jules L. Dienstag

266 papers receiving 25.5k citations

Hit Papers

An Assay for Circulating Antibodies to a Major Etiologic ... 1983 2026 1997 2011 1989 1985 1989 1999 2002 500 1000 1.5k 2.0k 2.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. An Assay for Circulating Antibodies to a Major Etiologic Virus of Human Non-A, Non-B Hepatitis
    1989 2.7k citations George Kuo, R H Purcell et al. profile →
  2. Viral Hepatitis and Liver Disease
    1985 1.6k citations Jules L. Dienstag et al. profile →
  3. Treatment of Chronic Hepatitis C with Recombinant Interferon Alfa
    1989 1.4k citations Eugene R. Schiff, Karen L. Lindsay et al. profile →
  4. Lamivudine as Initial Treatment for Chronic Hepatitis B in the United States
    1999 976 citations Jules L. Dienstag, Eugene R. Schiff et al. profile →
  5. Adherence to combination therapy enhances sustained response in genotype-1–infected patients with chronic hepatitis C
    2002 775 citations John G. McHutchison, Thierry Poynard et al. Gastroenterology profile →
  6. Hepatitis B Virus Infection
    2008 763 citations Jules L. Dienstag profile →
  7. A Preliminary Trial of Lamivudine for Chronic Hepatitis B Infection
    1995 680 citations Jules L. Dienstag, Eugene R. Schiff et al. profile →
  8. A Randomized, Controlled Trial of Interferon Alfa-2b Alone and after Prednisone Withdrawal for the Treatment of Chronic Hepatitis B
    1990 664 citations Karen L. Lindsay, Jules L. Dienstag et al. profile →
  9. Long-term safety of lamivudine treatment in patients with chronic hepatitis B
    2003 596 citations Anna S. Lok, Ching‐Lung Lai et al. Gastroenterology profile →
  10. Histological outcome during long-term lamivudine therapy
    2003 583 citations Jules L. Dienstag, Mary Woessner et al. Gastroenterology profile →
  11. Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis
    1992 418 citations Jules L. Dienstag, Michael Houghton et al. profile →
  12. Non-A, non-B hepatitis. I. Recognition, epidemiology, and clinical features
    1983 414 citations Jules L. Dienstag Gastroenterology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jules L. Dienstag United States 82 21.6k 21.0k 3.6k 1.5k 1.4k 268 27.2k
Eugene R. Schiff United States 78 22.8k 1.1× 22.5k 1.1× 3.2k 0.9× 1.3k 0.8× 898 0.6× 372 28.9k
David L. Thomas United States 72 21.7k 1.0× 21.0k 1.0× 4.2k 1.2× 1.2k 0.8× 2.6k 1.8× 292 27.3k
Patrick Marcellin France 99 34.2k 1.6× 34.3k 1.6× 4.1k 1.1× 1.4k 1.0× 1.3k 0.9× 635 38.8k
Jean–Michel Pawlotsky France 82 19.7k 0.9× 17.6k 0.8× 3.5k 1.0× 2.4k 1.6× 1.5k 1.1× 467 24.6k
Miriam J. Alter United States 60 18.4k 0.9× 17.6k 0.8× 3.5k 1.0× 779 0.5× 780 0.6× 117 22.4k
Geoffrey Dusheiko United Kingdom 60 15.1k 0.7× 14.6k 0.7× 2.4k 0.7× 1.1k 0.7× 1.6k 1.1× 285 18.6k
Mark Sulkowski United States 72 22.5k 1.0× 20.6k 1.0× 6.2k 1.7× 998 0.7× 983 0.7× 411 26.9k
Thierry Poynard France 93 33.9k 1.6× 36.1k 1.7× 2.8k 0.8× 2.0k 1.3× 1.1k 0.8× 427 43.7k
Heiner Wedemeyer Germany 82 23.1k 1.1× 19.8k 0.9× 4.5k 1.3× 1.8k 1.2× 3.9k 2.8× 840 29.2k
John G. McHutchison United States 95 37.2k 1.7× 33.6k 1.6× 4.7k 1.3× 2.6k 1.8× 3.0k 2.1× 467 43.6k

Countries citing papers authored by Jules L. Dienstag

Since Specialization
Citations

This map shows the geographic impact of Jules L. Dienstag's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jules L. Dienstag with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jules L. Dienstag more than expected).

Fields of papers citing papers by Jules L. Dienstag

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jules L. Dienstag. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jules L. Dienstag. The network helps show where Jules L. Dienstag may publish in the future.

Co-authorship network of co-authors of Jules L. Dienstag

This figure shows the co-authorship network connecting the top 25 collaborators of Jules L. Dienstag. A scholar is included among the top collaborators of Jules L. Dienstag based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jules L. Dienstag. Jules L. Dienstag is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Luther, Jay, Sanjoy K. Khan, Manish Gala, et al.. (2020). Hepatic gap junctions amplify alcohol liver injury by propagating cGAS-mediated IRF3 activation. Proceedings of the National Academy of Sciences. 117(21). 11667–11673. 69 indexed citations
2.
Shiffman, Mitchell L., Chihiro Morishima, Jules L. Dienstag, et al.. (2009). Effect of HCV RNA Suppression During Peginterferon Alfa-2a Maintenance Therapy on Clinical Outcomes in the HALT-C Trial. Gastroenterology. 137(6). 1986–1994. 30 indexed citations
3.
Lok, Anna S., Leonard B. Seeff, Timothy R. Morgan, et al.. (2008). Incidence of Hepatocellular Carcinoma and Associated Risk Factors in Hepatitis C-Related Advanced Liver Disease. Gastroenterology. 136(1). 138–148. 452 indexed citations
4.
Bourne, Eric, Jules L. Dienstag, Tamara Sander, et al.. (2006). Quantitative analysis of HBV cccDNA from clinical specimens: correlation with clinical and virological response during antiviral therapy. Journal of Viral Hepatitis. 14(1). 55–63. 43 indexed citations
5.
Wright, Teresa L., et al.. (2006). Advancing Patient Care: Integrating New Data. The American Journal of Gastroenterology. 101(S1). S32–S39. 8 indexed citations
6.
Lai, Ching‐Lung, Jules L. Dienstag, Eugene R. Schiff, et al.. (2003). Prevalence and Clinical Correlates of YMDD Variants during Lamivudine Therapy for Patients with Chronic Hepatitis B. Clinical Infectious Diseases. 36(6). 687–696. 497 indexed citations
7.
Dienstag, Jules L.. (2002). The role of liver biopsy in chronic hepatitis C. Hepatology. 36(Supplement 1). S152–S160. 283 indexed citations
8.
Rosenberg, Peter, James J. Farrell, Diane R. Abraczinskas, et al.. (2002). Rapidly progressive fibrosing cholestatic hepatitis-hepatitis C virus in HIV coinfection. The American Journal of Gastroenterology. 97(2). 478–483. 41 indexed citations
9.
McHutchison, John G., Thierry Poynard, Stephen Pianko, et al.. (2000). The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. Gastroenterology. 119(5). 1317–1323. 155 indexed citations
10.
Schiff, Eugene R., et al.. (1998). A Placebo Controlled Study of Lamivudine and Interferonalpha-2b in Patients with Chronic Hepatitis B Who PreviouslyFailed Interferon Therapy. Hepatology. 30 indexed citations
11.
Atkins, Mark, Nathaniel Brown, Mary Woessner, et al.. (1998). Clinical significance of YMDD mutant hepatitis B virus (HBV) in a large cohort of lamivudine-treated hepatitis B patients.. UCL Discovery (University College London). 13 indexed citations
12.
Dienstag, Jules L.. (1997). Sexual and perinatal transmission of hepatitis C. Hepatology. 26(Supplement 3). 66S–70S. 104 indexed citations
13.
Liang, T. Jake, Kiyoshi Hasegawa, Santiago J. Muñoz, et al.. (1994). Hepatitis B virus precore mutation and fulminant hepatitis in the United States. A polymerase chain reaction-based assay for the detection of specific mutation.. Journal of Clinical Investigation. 93(2). 550–555. 71 indexed citations
14.
Katkov, William N., Lawrence S. Friedman, Alison A. Evans, et al.. (1991). Elevated Serum Alanine Aminotransferase Levels in Blood Donors: The Contribution of Hepatitis C Virus. Annals of Internal Medicine. 115(11). 882–884. 31 indexed citations
15.
Seeff, Leonard B. & Jules L. Dienstag. (1988). Transfusion-associated non-A, non-B hepatitis. Where do we go from here?. PubMed. 95(2). 530–3. 9 indexed citations
16.
17.
Silverstein, Marc D., Albert G. Mulley, & Jules L. Dienstag. (1984). Should donor blood be screened for elevated alanine aminotransferase levels? A cost-effectiveness analysis.. PubMed. 252(20). 2839–45. 19 indexed citations
18.
Dienstag, Jules L.. (1977). Virus particles in marmoset hepatitis (reply). Nature. 267(5613). 730–730. 1 indexed citations
19.
Stevens, Cladd E., Charles E. Cherubin, Jules L. Dienstag, Robert H. Purcell, & W. Szmuness. (1977). Antibody to hepatitis A antigen in children. The Journal of Pediatrics. 91(3). 436–438. 13 indexed citations
20.
Purcell, R H, H. J. Alter, & Jules L. Dienstag. (1976). Non-A, non-B hepatitis.. PubMed. 49(3). 243–50. 126 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eugene R. Schiff Breakdown of academic impact, for papers by David L. Thomas Breakdown of academic impact, for papers by Patrick Marcellin Breakdown of academic impact, for papers by Jean–Michel Pawlotsky Breakdown of academic impact, for papers by Miriam J. Alter Breakdown of academic impact, for papers by Geoffrey Dusheiko Breakdown of academic impact, for papers by Mark Sulkowski Breakdown of academic impact, for papers by Thierry Poynard Breakdown of academic impact, for papers by Heiner Wedemeyer Breakdown of academic impact, for papers by John G. McHutchison
Rankless by CCL
2026